Proactive Investors - Run By Investors For Investors

VolitionRx hails 'best yet' in early colorectal cancer detection

In a study of 430 patients in Denmark, the test accurately detected 75% of colorectal adenomas
VolitionRx hails 'best yet' in early colorectal cancer detection
The trial was double blinded and age-adjusted with the results at 78% specificity
VolitionRx (NYSE:VNRX) has published another set of strong trial results for NuQ, its blood test for cancer.
In a study of 430 patients in Denmark, the test accurately detected 75% of colorectal adenomas, or pre-cancerous polyps, that were most likely to become cancerous.
A panel of five of NuQ biomarker assays also detected 86% of early colorectal cancers.
Hvidore University carried out the study to assess how effective was NuQ in detecting adenomas before they become cancerous.
The trial was double blinded and age-adjusted with the results at 78% specificity.
NuQ uses biomarker assays that can identify fragments of chromosomes, called nucleosomes, circulating in the blood and analyse them for epigenetic modifications that signal that cancer is present. The assays  require only a single drop of blood from patients, Volition added.
Professor Hans Jorgen Nielsen, Professor of Surgical Oncology at Hvidovre Hospital said: "This study shows extremely good detection of dangerous pre-cancer and early-stage cancer with the non-invasive NuQ blood test.”
We are now working with VolitionRx on large retrospective and prospective trials in both screening and symptomatic populations.
Cameron Reynolds, VolitionRx’s chief executive, said: "Not only do these results demonstrate our best detection rates to date for colorectal adenomas, but they further confirm the progress that VolitionRx is making in identifying new NuQ biomarker assays and optimizing panels to produce the most accurate detection rates of adenomas and colorectal cancers.”
Talking to Proactive, he added: "Just about every other biomarker out there detects late stage cancer much better than early stage purely because you have a lot more of the marker.
"So to have 86% of stage 1 cancers and 75% of pre-cancers is far better than we could have hoped for."
He noted particularly that the results of the adenomas, or pre-cancerous polyps were far better than the firm could have hoped for.
A commercial product for clinical use in detecting colorectal cancer is expected to be launched later this year.
Why Invest In VolitionRx? Read More Here

Register here to be notified of future VNRX Company articles
View full VNRX profile View Profile

VolitionRx Timeline

Related Articles

July 13 2017
M Pharma has in the year expanded its treatment portfolio, added significant revenue to the bottom line and received FDA pathway approval for its C-103
newspaper with word cancer magnified
July 11 2017
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
April 05 2017
The share placing follows a period of expansion that has seen it make two major acquisition

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use